1. Home
  2. SLNO vs TNET Comparison

SLNO vs TNET Comparison

Compare SLNO & TNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • TNET
  • Stock Information
  • Founded
  • SLNO 1999
  • TNET 1988
  • Country
  • SLNO United States
  • TNET United States
  • Employees
  • SLNO N/A
  • TNET N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • TNET Business Services
  • Sector
  • SLNO Health Care
  • TNET Consumer Discretionary
  • Exchange
  • SLNO Nasdaq
  • TNET Nasdaq
  • Market Cap
  • SLNO 3.8B
  • TNET 3.9B
  • IPO Year
  • SLNO 2014
  • TNET 2014
  • Fundamental
  • Price
  • SLNO $52.75
  • TNET $69.34
  • Analyst Decision
  • SLNO Strong Buy
  • TNET Hold
  • Analyst Count
  • SLNO 10
  • TNET 3
  • Target Price
  • SLNO $112.50
  • TNET $89.50
  • AVG Volume (30 Days)
  • SLNO 1.9M
  • TNET 400.5K
  • Earning Date
  • SLNO 11-05-2025
  • TNET 10-24-2025
  • Dividend Yield
  • SLNO N/A
  • TNET 1.54%
  • EPS Growth
  • SLNO N/A
  • TNET N/A
  • EPS
  • SLNO N/A
  • TNET 2.85
  • Revenue
  • SLNO $32,656,999.00
  • TNET $4,993,000,000.00
  • Revenue This Year
  • SLNO N/A
  • TNET $2.47
  • Revenue Next Year
  • SLNO $175.39
  • TNET $3.23
  • P/E Ratio
  • SLNO N/A
  • TNET $25.12
  • Revenue Growth
  • SLNO N/A
  • TNET 0.73
  • 52 Week Low
  • SLNO $41.50
  • TNET $62.55
  • 52 Week High
  • SLNO $90.32
  • TNET $99.78
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 24.40
  • TNET 52.42
  • Support Level
  • SLNO $50.63
  • TNET $67.36
  • Resistance Level
  • SLNO $72.99
  • TNET $72.84
  • Average True Range (ATR)
  • SLNO 4.32
  • TNET 1.93
  • MACD
  • SLNO -1.06
  • TNET 0.01
  • Stochastic Oscillator
  • SLNO 9.34
  • TNET 44.25

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About TNET TriNet Group Inc.

TriNet offers outsourced payroll and human capital management solutions for small and midsize businesses via a professional employer organization model. Under the PEO model, TriNet enters a co-employment arrangement and acts as the employer of record for administrative and regulatory purposes for clients' employees, known as worksite employees. Clients leverage the scale and expertise of TriNet to access competitive employee benefits, share employment risk liability, access compliance support, and outsource mission-critical day-to-day HR functions such as payroll and tax administration. Following the acquisition of Zenefits and Clarus R+D in 2022, TriNet derives the minority of its revenue from self-service HCM software and R&D tax credit services.

Share on Social Networks: